RNA (Atrium Therapeutics) Revenue: $20.49 Mil (TTM As of Mar. 2026)


RNA Atrium Therapeutics Inc RNA
12 GF Score
Price $13.57
! 1 Warning Sign
View Full Analysis

What is Atrium Therapeutics Revenue?

Atrium Therapeutics RNA -0.59% 12 Revenue is $20.49 Mil as of Mar. 2026. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Atrium Therapeutics's revenue for the three months ended in Mar. 2026 was $19.64 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $20.49 Mil. Atrium Therapeutics's Revenue per Share for the three months ended in Mar. 2026 was $1.15. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.20.

During the past 12 months, the average Revenue per Share Growth Rate of Atrium Therapeutics was 71.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

Atrium Therapeutics  (NAS:RNA) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Atrium Therapeutics Revenue Related Terms

Atrium Therapeutics Revenue Historical Data

* Premium members only.

The historical data trend for Atrium Therapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrium Therapeutics Revenue Chart

Atrium Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Revenue
9.76 10.90 18.62

Atrium Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
Revenue Get a 7-Day Free Trial 2.97 1.57 0.00 0.86 19.64

RNA vs CNTN, QTTB, TARA: Revenue Comparison

For the Biotechnology subindustry, Atrium Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atrium Therapeutics Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atrium Therapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where Atrium Therapeutics's Revenue falls into.


RNA
12GF Score
Atrium Therapeutics Inc RNA
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrium Therapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $20.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $20.49 Mil mean?
Atrium Therapeutics (RNA) has a Revenue of $20.49 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Atrium Therapeutics and its competitors.
Is Atrium Therapeutics' Revenue too high?
Atrium Therapeutics' current Revenue is $20.49 Mil. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' Revenue compare to CNTN and QTTB?
Atrium Therapeutics' Revenue of $20.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Atrium Therapeutics and its competitors. Atrium Therapeutics's current Revenue is $20.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current Revenue of $20.49 Mil. The current Revenue is $20.49 Mil. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current Revenue is $20.49 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atrium Therapeutics Business Description

Address 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score

Get the complete analysis for RNA

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.57
Price